Target sites for manipulating apoptosis in prostate cancer

BJU International, Supplement

Volumn 85, Issue 2, 2000, Pages 38-44

  Watson, R W G ^a   Fitzpatrick, J M ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CASPASE; FAS ANTIGEN; INTEGRIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN; TUMOR NECROSIS FACTOR;

APOPTOSIS; CELL GROWTH; CELL PROLIFERATION; EPITHELIUM CELL; GENE CONTROL; HUMAN; MALE; MITOCHONDRION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW;

EID: 0034072108     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.2000.00057.x     Document Type: Review

References (61)

1. 1 Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28: 251-65
2. 2 Berges RR, Vukanovic J, Epstein JI et al. Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473-80
3. 3 Gerschenson LE, Rotello RJ. Apoptosis: a different type of cell death. FASEB J 1992; 6: 2450-5
4. 4 Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-26
5. 5 Cohen JJ. Apoptosis. Immunol Today 1993; 14: 126-30
6. 6 Hengartner MO, Horvitz HR. C. elegans cell survival gene ced-9 encodes a functional homologue of the mammalian proto-oncogene bcl-2. Cell 1994; 76: 665-76
7. 7 Vaux DL. Towards an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 1993; 90: 786-9
8. 8 White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996; 10: 1-15
9. 9 Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1991; 348: 331-3
10. 10 Hockenbery DM, Oltvai ZN, Yin X et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-51
11. 11 Riparbelli MG, Callaini G, Tripodi SA et al. Localization of the Bcl-2 protein to the outer mitochondrial membrane by electron microscopy. Exp Cell Res 1995; 221: 363-9
12. 12 Clem RJ, Cheng EH, Karp CL et al. Modulation of cell death by Bcl-xl through caspase interaction. Proc Natl Acad Sci USA 1998; 95: 554-9
13. 13 Ng FWH, Nguyen M, Kwan T et al. P28 BAP 31, aBcl-2/Bcl XL and procaspase-8-associated protein in the endoplasmic reticulum. J Cell Biol 1997; 139: 327-38
14. 14 Han DKM, Chaudhary PM, Wright ME et al. MRIT, a novel death-effector domain-containing protein, interacts with caspase and Bcl XL and initiates cell death. Proc Natl Acad Sci USA 1997; 94: 11333-8
15. 15 McDonnall TJ, Troncoso P, Brisbay SM et al. Expression of proto-oncogene bcl-2 in the prostate and its association with emergency of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4
16. 16 Colombel M, Symmons F, Gil S et al. Detection of apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143: 390-400
17. 17 Furuya Y, Krajewski S, Epstein JI et al. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996; 2: 389-98
18. 18 Clem RJ, Miller LK. Control of programmed cell death by the baculovirus genes p35 and IAP. Mol Cell Biol 1994; 14: 5212-22
19. 19 Deveraux QL, Takahashi R, Salvesen GS et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-3
20. 20 Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survival, expressed in cancer and lymphoma. Nature Med 1997; 3: 917-21
21. 21 Getzenberg RH, Pienta KJ, Coffey DS. The tissue matrix: cell dynamics and hormone action. Endocrine Rev 1990; 11: 399-417
22. 22 Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-26
23. 23 Guenette RS, Mooibroek M, Wong K et al. Cathepsin B, a cysteine protease implicated in metastatic progression, is also expressed during regression of the rat prostate and mammary gland. Eur J Biochem 1994; 226: 311-21
24. 24 Pietrzkowski Z, Wernicke D, Porcu P et al. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res 1992; 52: 6447-51
25. 25 Even G, Harrington E, Fanidi A et al. Integrated control of cell proliferation and cell death by the c-myc oncogene. Roy Soc Lond B Biol Sci 1994; 345: 269-75
26. 26 Chan J, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 1998; 279: 563-6
27. 27 Lui Y, Lehar S, Corvi C et al. Expression of the insulin-like growth factor 1 receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells. Cancer Res 1998; 58: 570-6
28. 28 Levine AJ, Momand J, Findlay CA. The p53 tumor suppressor gene. Nature 1995; 351: 453-6
29. 29 Kubota Y, Shuin T, Uemura H et al. Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 1995; 27: 18-24
30. 30 Colombel M, Radvanyi F, Blanche M et al. Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 1995; 10: 1269-74
31. 31 Sikora K, Pandha H. Gene therapy for prostate cancer. Br J Urol 1997; 79: 64-8
32. 32 Phillips SM, Bartin CM, Lee SJ et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994; 70: 1252-7
33. 33 Rubin SJ, Hallahan DE, Ashman CR et al. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991; 46: 3136
34. 34 Martikainen P, Kyprianou N, Tucker RW et al. Programmed death of non-proliferating androgen independent prostatic cancer cells. Cancer Res 1991; 51: 4693-700
35. 35 Furuya Y, Lundmo P, Short AD et al. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cell induced by thapsigargin. Cancer Res 1994; 54: 6167-75
36. 36 Nagata S, Golstein P. The Fas death factor. Science 1995 ; 267: 1449-56
37. 37 Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1993; 179: 873-9
38. 38 Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1994; 57: 129-44
39. 39 Vignaux F, Vivier E, Malissen B et al. TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med 1995; 181: 781-6
40. 40 Alderson MR, Tough TW, Davis-Smith T et al. Fas ligand mediated activation-induced cell death in human T Lymphocytes. J Exp Med 1995; 181: 71-7
41. 41 Dhein J, Walczak H, Baumler C et al. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995; 373: 438-41
42. 42 Nagata S, Takashi S. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1994; 16: 39-43
43. 43 Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-12
44. 44 Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NK-κB activation. Cell 1995; 81: 495-504
45. 45 Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 1996; 85: 803-15
46. 46 Muzio M, Chinnaiyan AM, Kischkel FC et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-28
47. 47 Alnemri ES, Livingston DJ, Nicholson DW et al. Human ICE/ CED-3 protease nomenclature. Cell 1996; 87: 171
48. 48 Takeuchi T, Sasaki Y, Ueki T et al. Modulation of growth and apoptosis response in PC-3 and LNCaP prostate-cancer cell lines. Int J Cancer 1996; 67: 709-14
49. 49 Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997; 18: 44-51
50. 50 Li P, Nijhawan D, Budihardjo I et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-89
51. 51 Green D, Kroemer G. The central executioner of apoptosis: caspases or mitochondria? Trends Cell Biol 1998; 8: 267-71
52. 52 Marchetti P, Castedo M, Susin SA et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996; 184: 1150-60
53. 53 Salvesen GS, Dixit VM. Caspases: Intracellular signaling by proteolysis. Cell 1997; 91: 443-6
54. 54 Henkart PA. ICE family proteases: mediators of all apoptotic cell death. Immunity 1996; 4: 195-201
55. 55 Armstrong RC, Aja T, Xiang J et al. Fas-induced activation of the cell death-related protease CPP.32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 1996; 271: 16850-5
56. 56 Zhou Q, Snipas S, Orth K et al. Target protease specificity of the viral serpin CrmA. J Biol Chem 1997; 272: 7797-800
57. 57 Krajewska M, Wang G, Krajewski S et al. Immunohistochemical analysis of in vivo patterns of expression of CCP32 (caspase-3), a cell death protease. Cancer Res 1997; 57: 1605-13
58. 58 Coffey R, Watson RWG, Murphy E et al. Diethylmaleate, a glutathione depleting agent, induces apoptosis in adenocarcinoma prostate cancer cell lines. Br J Cancer 1998; 78: 7
59. 59 Marcelli M, Cunningham GR, Haidacher SJ et al. Caspase 7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 1998; 58: 76-83
60. 60 Srikanth S, Kraft AS. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res 1998; 58:834-9
61. 61 MacCorkle RA, Freeman KW, Spencer DM. Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci USA 1998; 95: 3655-60